Key insights
- The author argues Cincinnati Financial (CINF) is undervalued, trading at a low P/E of 10.9x despite a 30% earnings CAGR driven by strong underwriting and rising investment income. The piece suggests a potential 1.8x-2.0x upside as the market re-rates the stock to a more appropriate valuation, assuming continued earnings growth and a modest P/E expansion. This presents a bullish signal for the stock.
The Thesis
CINF is compounding earnings at 30% annually while the market prices it like a stagnant utility at P/E 10.9x. That's a valuation disconnect begging to close.
Recent proof:
- Q1 2026: $3.37 EPS vs $2.89 consensus → +16.6% beat
- Q4 2025: $2.85 EPS vs $2.06 consensus → +38% beat
- FY2025: $15.17 EPS (vs $11.66 in 2023) → 30% CAGR
Why the growth?
Two things: (1) strong underwriting, their combined loss ratio improved from 113% to 95.6%, meaning they're pricing insurance better and paying out fewer claims. (2) Investment income from a rising rate environment. Both are sustainable-ish.
The valuation:
- P/E: 10.9x (S&P 500 avg ~19x)
- P/B: 1.6x (fair for quality)
- FCF: $1.4B on $12.6B revenue (solid conversion)
The 2x Math (Conservative)
Current: $173 stock price, $15.17 EPS
In 3-4 years (if growth moderates to 13-15% CAGR):
- EPS: $15.17 → ~$22-25
- P/E re-rates from 10.9x → 14x (still 1 full turn below historical average)
- Target: $308-350
That's 1.8x–2.0x upside without needing anything exotic—just normal earnings growth + normal re-rating.
Why Is It Cheap?
Insurance stocks are out of favor. When rates are stable (not spiking), insurance gets no attention. The market has priced in worst-case scenarios:
- Rate shock (hasn't happened)
- Catastrophe cluster (hasn't materialized)
- Margin compression (evidence of pricing power instead)
CINF keeps beating despite these fears, but the valuation hasn't caught up.
The Play
This is textbook value investing: a quality business compounding earnings at 30% while trading at a cyclical (low) valuation.
No turnaround needed. No binary bets. Just a boring insurance compounder re-rating as the market catches up to reality.
Does CINF deserve 11x P/E while growing 30%+? Thoughts?